--- title: "DBV Technologies Nears Viaskin Peanut Resubmission As Funding Risks Linger" type: "News" locale: "en" url: "https://longbridge.com/en/news/281663494.md" description: "DBV Technologies is set to resubmit its Biologics License Application for the Viaskin Peanut Patch after addressing FDA concerns, following positive Phase 3 trial results. The company reported a net loss of $146.95 million on $5.64 million in sales for 2025, raising funding risks. The stock price is currently €3.635, with a 171.3% return over the past year. Key factors to watch include the BLA resubmission date, FDA review milestones, and potential impacts on commercialization in the pediatric peanut allergy market." datetime: "2026-04-03T21:57:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281663494.md) - [en](https://longbridge.com/en/news/281663494.md) - [zh-HK](https://longbridge.com/zh-HK/news/281663494.md) --- # DBV Technologies Nears Viaskin Peanut Resubmission As Funding Risks Linger - DBV Technologies plans to resubmit its Biologics License Application to the FDA for the Viaskin Peanut Patch for children after addressing earlier regulatory concerns. - The resubmission follows positive Phase 3 VITESSE trial results and a strengthened financial position. - Regulatory clearance for Viaskin Peanut could open a path to commercializing the patch in the pediatric peanut allergy market. For investors tracking ENXTPA:DBV, the planned BLA resubmission comes at a time when the share price is €3.635 and the stock has returned 171.3% over the past year. Returns are 11.3% year to date and 15.7% over three years, while the five year return shows a 64.2% decline, underlining a history that has included both sharp gains and setbacks. The combination of recent clinical progress, regulatory engagement and a stronger balance sheet places DBV Technologies at a potentially important juncture. As the FDA reviews the updated filing, investors may monitor signals on approval timing, labeling and any post marketing requirements that could influence the commercial opportunity for Viaskin Peanut. Stay updated on the most important news stories for DBV Technologies by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on DBV Technologies. ENXTPA:DBV 1-Year Stock Price Chart Is DBV Technologies's balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis. The planned resubmission of the Viaskin Peanut BLA shifts attention firmly to regulatory risk and funding capacity. The company has addressed earlier FDA concerns around patch adherence and is now leaning on positive Phase 3 VITESSE data and what it describes as a stronger financial position. At the same time, DBV recently reported full year 2025 sales of US$5.64 million and a net loss of US$146.95 million, following a US$113.92 million loss the year before, so the earnings profile remains heavily loss making. That makes the timing of any FDA decision and subsequent commercialization especially important, because extended review periods, restrictive labeling or post marketing commitments could prolong cash burn before any meaningful revenue contribution from Viaskin Peanut. ### The Risks and Rewards Investors Should Consider - ⚠️ The business reported a full year 2025 net loss of US$146.95 million on US$5.64 million of sales, so the gap between revenue and expenses is wide and keeps funding risk in focus. - ⚠️ Analysts have flagged less than one year of cash runway and previous shareholder dilution, which together point to the possibility of further capital raising if regulatory timelines or uptake are slower than hoped. - 🎁 Positive Phase 3 VITESSE results and progress toward BLA resubmission provide a clearer regulatory path for Viaskin Peanut, which could support future commercialization in the pediatric peanut allergy market. - 🎁 Addition to the SBF 120 Index and renewed interest from brokers highlight growing market attention, which may help DBV access capital markets if further funding is required. ### What To Watch Going Forward From here, the key items to watch are the formal BLA resubmission date, the FDA’s review milestones and any feedback on labeling or safety that might limit the eligible patient pool for Viaskin Peanut. Investors may also want to track quarterly cash usage, financing transactions and how DBV positions the patch against established therapies such as Palforzia and Xolair in terms of convenience and reimbursement. Progress on reimbursement discussions and early commercial preparations, if disclosed, could give clues on how quickly Viaskin Peanut might contribute to sales once any regulatory hurdles are cleared. To ensure you're always in the loop on how the latest news impacts the investment narrative for DBV Technologies, head to the community page for DBV Technologies to never miss an update on the top community narratives. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [DBVT.US](https://longbridge.com/en/quote/DBVT.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [LABD.US](https://longbridge.com/en/quote/LABD.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [ADVB.US](https://longbridge.com/en/quote/ADVB.US.md) ## Related News & Research - [Artiva says AB-101 plus rituximab posts 71% ACR50 response in refractory RA study](https://longbridge.com/en/news/286959967.md) - [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition](https://longbridge.com/en/news/286608288.md) - [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)